Year All2024202320222021 KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference 01-11-2022 KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022” 01-06-2022 KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program 12-20-2021 KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX” 12-14-2021 KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021 12-13-2021 KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida 12-13-2021 KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates 11-10-2021 KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD 11-05-2021 KemPharm to Report Third Quarter 2021 Results 11-03-2021 AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress 10-27-2021
KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference 01-11-2022
KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX” 12-14-2021
KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD 11-05-2021
AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress 10-27-2021
